查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1961271

非處方止痛藥市場－全球產業規模、佔有率、趨勢、機會與預測：按藥物類型、通路、地區和競爭格局分類，2021-2031年

Over-the-Counter Analgesics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Drug Type, By Distribution Channel, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球非處方止痛藥市場預計將從 2025 年的 211.9 億美元成長到 2031 年的 355.6 億美元，複合年成長率為 9.01%。

這些藥物被定義為非處方處方箋（OTC），旨在無需醫生直接指導即可緩解輕度至中度疼痛、發燒和發炎。市場成長趨勢主要受人口結構變化驅動，尤其是全球人口快速老化，導致慢性肌肉骨骼疾病的盛行率上升；此外，公共衛生政策的策略性轉變，即鼓勵自我治療以降低成本，也是推動市場成長的重要因素。這一以消費者主導的醫療保健趨勢得到了可靠的區域數據支持。例如，根據歐洲自我護理產業協會（AESC）的報告，預計到2025年，歐洲非處方藥市場將成長8.4%，規模達到710億美元。

市場概覽
預測期 2027-2031
市場規模：2025年 211.9億美元
市場規模：2031年 355.6億美元
複合年成長率：2026-2031年 9.01%
成長最快的細分市場 醫院藥房
最大的市場 北美洲

然而，監管機構加強了對產品安全和預防誤用的監管，這給市場帶來了巨大的障礙。為了降低意外過量和成癮等風險，監管機構正在收緊對標籤要求的執行力度，並限制包裝尺寸，尤其是針對聯合治療。這些合規義務給製造商帶來了沉重的負擔，導致產品核可延遲和營運成本增加。因此，這些監管壓力實際上延緩了創新止痛方案進入大眾消費市場。

市場促進因素

人口老化以及隨之而來的與老齡化相關的疼痛疾病的增加，顯著擴大了非處方止痛藥的消費群。隨著全球預期壽命的延長，慢性肌肉骨骼疾病（例如骨關節炎和腰痛）的盛行率不斷上升，使得人們更需要便捷的長期疼痛管理策略。這群人擴大使用局部和全身性非類固醇消炎劑(NSAIDs) 來維持活動能力和生活品質，同時盡量減少就醫次數，從而為成熟品牌創造了穩定的需求。行業領導者的財務成功也反映了這種持續的依賴性；根據 Haleon 公司於 2025 年 2 月發布的 2024 會計年度年度報告和 20-F 表格，該公司疼痛管理業務在該會計年度累計了26 億英鎊的收入。

同時，自我治療和消費者主導醫療保健的全球趨勢正在改變市場動態。在減輕醫療系統負擔的需求以及數位健康素養提升的推動下，越來越多的消費者開始主動管理輕微疾病和急性疼痛。零售商店和電商平台便捷地提供各種止痛藥，進一步促進了這一轉變，使消費者能夠進行主動健康管理。高銷量也印證了這個趨勢。歐洲自我護理產業協會（AESGP）在2024年度報告（2025年6月發布）中指出，上年度歐洲非處方藥的銷售量達到47億盒。同樣，利潔時集團（Reckitt Benckiser Group PLC）在2025年3月發布的報告顯示，其醫療保健業務部門2024年的收入淨額為58.82億英鎊。

市場挑戰

對產品安全和誤用風險日益嚴格的監管是全球非處方止痛藥市場成長的主要障礙。監管機構正在執行嚴格的標籤要求並限制包裝尺寸，尤其旨在降低諸如複方處方藥意外過量服用等風險。這些合規要求迫使製造商投入大量資源來滿足安全標準，導致營運成本增加，並佔用了本應用於研發的資金。因此，新產品的核准流程延長，延緩了先進止痛方案進入大眾市場的進程。

儘管消費者對自我治療策略的依賴仍然很強，但監管瓶頸限制了產品的供應，從而直接阻礙了市場成長。近期消費者統計數據凸顯了社會對便利止痛藥物的高需求與商業化進展緩慢之間的差距。英國藥品協會預測，到2025年，91%的成年人將使用非處方藥治療輕微健康問題。雖然如此廣泛的使用表明市場具有巨大的擴張潛力，但嚴格的安全法規帶來的財務和物流限制使得製造商無法完全滿足市場需求，從而抑制了整個行業的收入成長。

市場趨勢

隨著消費者和醫療保健提供者尋求降低長期服用口服非類固醇抗發炎藥 (NSAIDs) 帶來的全身性風險，市場正經歷著局部用藥製劑的重大轉變。這項轉變的特點是，人們越來越傾向於選擇經皮吸收貼片、凝膠和噴霧劑，這些製劑無需經過胃腸道或肝臟代謝即可提供局部鎮痛。領先的經皮品牌的強勁表現證明了這種更安全的給藥方式的商業性成功。例如，2024 年 10 月，久光製藥公佈其旗艦產品Salonpas)的銷售額同比成長 17%，凸顯了患者擴大依賴非全身性鎮痛替代方案的趨勢。

同時，在「潔淨標示」運動的推動下，以及消費者對植物來源抗發炎藥物日益成長的偏好，將天然植物成分融入止痛產品線的趨勢愈發明顯。製造商正積極收購和開發含有薑黃和薄荷醇等活性成分的產品，以吸引那些除了緩解症狀外，更注重整體健康的健康意識消費者。這種向天然成分功效的策略轉變，正為產業巨頭帶來實際的經濟效益。例如，賽諾菲消費者保健部門在2024年7月發布的公佈財報中顯示，銷售額成長了9.6%，這主要得益於其旗艦薑黃保健品牌家樂（Knorr）兩位數的成長。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球非處方止痛產品市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 藥物類型（乙醯胺酚、非類固醇消炎劑（NSAIDs）、水楊酸鹽和其他鎮痛藥）
    • 分銷通路（醫院藥局、零售藥局、網路藥局）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美非處方止痛藥市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲非處方止痛藥市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區非處方止痛藥市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲非處方止痛產品市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲非處方止痛藥市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章 全球非處方止痛藥市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Bayer AG
  • Boehringer Ingelheim International GmbH
  • Johnson & Johnson Services Inc
  • GSK plc
  • Pfizer Inc.
  • Sanofi SA
  • Sun Pharmaceutical Industries Ltd.
  • Takeda Pharmaceutical Company Limited
  • AstraZeneca PLC
  • Merck & Co Inc.

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 17073

The Global Over-the-Counter (OTC) Analgesics Market is projected to expand from a valuation of USD 21.19 Billion in 2025 to USD 35.56 Billion by 2031, reflecting a CAGR of 9.01%. These pharmaceutical formulations are defined as non-prescription treatments intended to relieve mild to moderate pain, fever, and inflammation without direct medical oversight. The market's upward trajectory is primarily driven by demographics, specifically a rapidly aging global population prone to chronic musculoskeletal issues, alongside a strategic pivot in public health policy that encourages self-medication to lower healthcare expenses. This trend toward consumer-led health management is reinforced by robust regional data; for instance, the Association of the European Self-Care Industry reported that the European OTC market grew by 8.4% in 2025, reaching a value of $71 billion.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 21.19 Billion
Market Size 2031USD 35.56 Billion
CAGR 2026-20319.01%
Fastest Growing SegmentHospital Pharmacies
Largest MarketNorth America

However, the market faces significant hurdles due to intensified regulatory scrutiny focused on product safety and the prevention of misuse. Regulatory authorities are increasingly enforcing strict labeling requirements and limiting pack sizes to mitigate risks such as accidental overdose or dependency, particularly regarding combination therapies. These compliance obligations place a heavy burden on manufacturers, resulting in delayed product approvals and escalated operational costs. Consequently, these regulatory pressures effectively decelerate the introduction of innovative pain relief solutions to the broader consumer market.

Market Driver

The expanding geriatric population and the concurrent rise in age-related pain conditions are significantly widening the consumer base for OTC analgesics. As global life expectancy rises, the prevalence of chronic musculoskeletal disorders, such as osteoarthritis and back pain, increases, creating a necessity for accessible, long-term pain management strategies. This demographic increasingly utilizes topical and systemic NSAIDs to preserve mobility and quality of life while minimizing the need for frequent physician consultations, thereby generating consistent demand for established brands. The financial success of category leaders reflects this sustained reliance; according to Haleon's 'Annual Report and Form 20-F 2024' published in February 2025, their Pain Relief business unit generated £2.6 billion in revenue for the fiscal year.

Concurrently, a decisive global trend toward self-medication and consumer healthcare autonomy is transforming market dynamics. Driven by the necessity to alleviate pressure on healthcare systems and supported by enhanced digital health literacy, consumers are increasingly managing minor ailments and acute pain independently. This shift is further fueled by the broad availability of various analgesic formats across retail and e-commerce platforms, which facilitates proactive health management. High sales volumes confirm this behavior; the Association of the European Self-Care Industry (AESGP) noted in its 'Annual Report 2024' (June 2025) that 4.7 billion packs of non-prescription medicines were sold in Europe the previous year. Similarly, Reckitt Benckiser Group PLC reported in March 2025 that its Health business unit achieved net revenue of £5,882 million in 2024.

Market Challenge

Increased regulatory scrutiny regarding product safety and the potential for misuse presents a formidable obstacle to the growth of the Global Over-the-Counter Analgesics Market. Authorities are rigorously implementing strict labeling mandates and restricting pack sizes to reduce risks such as accidental overdoses, specifically with combination formulas. These compliance requirements force manufacturers to allocate significant resources toward meeting safety standards, thereby driving up operational costs and diverting capital that would otherwise be used for research and development. As a result, the approval timeline for new products is extended, which delays the introduction of advanced pain relief options to the mass market.

This regulatory bottleneck directly inhibits growth by restricting product availability, even as consumer reliance on self-medication strategies remains strong. The gap between the high public demand for accessible pain management and the decelerated pace of commercialization is highlighted by recent consumption statistics. According to the Proprietary Association of Great Britain, 91% of adults reported utilizing over-the-counter products for minor health conditions in 2025. Although such extensive usage indicates immense potential for market expansion, the financial and logistical constraints imposed by stringent safety regulations prevent manufacturers from fully capitalizing on this demand, effectively moderating the sector's overall revenue progression.

Market Trends

The market is undergoing a significant shift toward topical formulations as both consumers and healthcare providers aim to reduce the systemic risks linked to long-term oral NSAID use. This transition is marked by a preference for transdermal patches, gels, and sprays, which provide targeted pain relief while bypassing gastrointestinal and hepatic metabolic processes. The commercial success of this safer delivery method is demonstrated by the strong performance of leading transdermal brands; for instance, Hisamitsu Pharmaceutical reported in October 2024 that revenue for its flagship product, Salonpas, rose by 17% year-on-year, highlighting the increasing patient reliance on non-systemic pain management alternatives.

In parallel, there is a marked integration of natural and botanical ingredients into analgesic product lines, fueled by the "clean label" movement and growing consumer preference for plant-based anti-inflammatory options. Manufacturers are actively acquiring or developing products containing agents such as turmeric and menthol to appeal to health-conscious demographics who value holistic wellness alongside symptomatic relief. This strategic pivot toward nature-derived efficacy is generating tangible financial gains for major industry players; Sanofi's Consumer Healthcare division, for example, reported a 9.6% sales increase in its July 2024 earnings release, a performance significantly driven by the double-digit growth of Qunol, a leading turmeric-based health brand.

Key Market Players

  • Bayer AG
  • Boehringer Ingelheim International GmbH
  • Johnson & Johnson Services Inc
  • GSK plc
  • Pfizer Inc.
  • Sanofi SA
  • Sun Pharmaceutical Industries Ltd.
  • Takeda Pharmaceutical Company Limited
  • AstraZeneca PLC
  • Merck & Co Inc.

Report Scope

In this report, the Global Over-the-Counter (OTC) Analgesics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Over-the-Counter (OTC) Analgesics Market, By Drug Type

  • Acetaminophen
  • Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
  • Salicylates and Other Analgesics

Over-the-Counter (OTC) Analgesics Market, By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Over-the-Counter (OTC) Analgesics Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Over-the-Counter (OTC) Analgesics Market.

Available Customizations:

Global Over-the-Counter (OTC) Analgesics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Over-the-Counter (OTC) Analgesics Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Drug Type (Acetaminophen, Nonsteroidal Anti-inflammatory Drugs (NSAIDs), Salicylates and Other Analgesics)
    • 5.2.2. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Over-the-Counter (OTC) Analgesics Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Drug Type
    • 6.2.2. By Distribution Channel
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Over-the-Counter (OTC) Analgesics Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Drug Type
        • 6.3.1.2.2. By Distribution Channel
    • 6.3.2. Canada Over-the-Counter (OTC) Analgesics Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Drug Type
        • 6.3.2.2.2. By Distribution Channel
    • 6.3.3. Mexico Over-the-Counter (OTC) Analgesics Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Drug Type
        • 6.3.3.2.2. By Distribution Channel

7. Europe Over-the-Counter (OTC) Analgesics Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Drug Type
    • 7.2.2. By Distribution Channel
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Over-the-Counter (OTC) Analgesics Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Drug Type
        • 7.3.1.2.2. By Distribution Channel
    • 7.3.2. France Over-the-Counter (OTC) Analgesics Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Drug Type
        • 7.3.2.2.2. By Distribution Channel
    • 7.3.3. United Kingdom Over-the-Counter (OTC) Analgesics Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Drug Type
        • 7.3.3.2.2. By Distribution Channel
    • 7.3.4. Italy Over-the-Counter (OTC) Analgesics Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Drug Type
        • 7.3.4.2.2. By Distribution Channel
    • 7.3.5. Spain Over-the-Counter (OTC) Analgesics Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Drug Type
        • 7.3.5.2.2. By Distribution Channel

8. Asia Pacific Over-the-Counter (OTC) Analgesics Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Drug Type
    • 8.2.2. By Distribution Channel
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Over-the-Counter (OTC) Analgesics Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Drug Type
        • 8.3.1.2.2. By Distribution Channel
    • 8.3.2. India Over-the-Counter (OTC) Analgesics Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Drug Type
        • 8.3.2.2.2. By Distribution Channel
    • 8.3.3. Japan Over-the-Counter (OTC) Analgesics Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Drug Type
        • 8.3.3.2.2. By Distribution Channel
    • 8.3.4. South Korea Over-the-Counter (OTC) Analgesics Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Drug Type
        • 8.3.4.2.2. By Distribution Channel
    • 8.3.5. Australia Over-the-Counter (OTC) Analgesics Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Drug Type
        • 8.3.5.2.2. By Distribution Channel

9. Middle East & Africa Over-the-Counter (OTC) Analgesics Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Drug Type
    • 9.2.2. By Distribution Channel
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Over-the-Counter (OTC) Analgesics Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Drug Type
        • 9.3.1.2.2. By Distribution Channel
    • 9.3.2. UAE Over-the-Counter (OTC) Analgesics Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Drug Type
        • 9.3.2.2.2. By Distribution Channel
    • 9.3.3. South Africa Over-the-Counter (OTC) Analgesics Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Drug Type
        • 9.3.3.2.2. By Distribution Channel

10. South America Over-the-Counter (OTC) Analgesics Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Drug Type
    • 10.2.2. By Distribution Channel
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Over-the-Counter (OTC) Analgesics Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Drug Type
        • 10.3.1.2.2. By Distribution Channel
    • 10.3.2. Colombia Over-the-Counter (OTC) Analgesics Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Drug Type
        • 10.3.2.2.2. By Distribution Channel
    • 10.3.3. Argentina Over-the-Counter (OTC) Analgesics Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Drug Type
        • 10.3.3.2.2. By Distribution Channel

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Over-the-Counter (OTC) Analgesics Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Bayer AG
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Boehringer Ingelheim International GmbH
  • 15.3. Johnson & Johnson Services Inc
  • 15.4. GSK plc
  • 15.5. Pfizer Inc.
  • 15.6. Sanofi SA
  • 15.7. Sun Pharmaceutical Industries Ltd.
  • 15.8. Takeda Pharmaceutical Company Limited
  • 15.9. AstraZeneca PLC
  • 15.10. Merck & Co Inc.

16. Strategic Recommendations

17. About Us & Disclaimer